Healthcare [ 2/11 ] | Biotechnology [ 32/154 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 22 | -0.42
Increased by
+23.64%
|
-0.10
Decreased by
-320.00%
|
| Aug 11, 22 | -0.60
Decreased by
-30.43%
|
-0.39
Decreased by
-53.85%
|
| May 12, 22 | -0.25
Increased by
+44.44%
|
-0.19
Decreased by
-31.58%
|
| Mar 17, 22 | -0.52
Decreased by
-92.59%
|
-0.30
Decreased by
-73.33%
|
| Nov 10, 21 | -0.55
Decreased by
-96.43%
|
0.01
Decreased by
-5.60 K%
|
| Aug 10, 21 | -0.46
Increased by
+13.21%
|
-0.40
Decreased by
-15.00%
|
| May 13, 21 | -0.45
Decreased by
-50.00%
|
-0.36
Decreased by
-25.00%
|
| Mar 18, 21 | -0.27
Increased by
+18.18%
|
-0.31
Increased by
+12.90%
|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 8.37 M
Decreased by
-1.75%
|
-13.27 M
Increased by
+1.64%
|
Decreased by
-158.64%
Decreased by
-0.11%
|
| Jun 30, 22 | 5.29 M
Decreased by
-26.43%
|
-18.10 M
Decreased by
-64.09%
|
Decreased by
-341.99%
Decreased by
-123.04%
|
| Mar 31, 22 | 13.63 M
Increased by
+325.37%
|
-7.53 M
Increased by
+29.28%
|
Decreased by
-55.23%
Increased by
+83.37%
|
| Dec 31, 21 | -3.99 M
Decreased by
-170.64%
|
-15.17 M
Decreased by
-139.15%
|
Increased by
+380.51%
Increased by
+438.57%
|
| Sep 30, 21 | 8.52 M
Increased by
+345.16%
|
-13.49 M
Decreased by
-119.88%
|
Decreased by
-158.45%
Increased by
+50.61%
|
| Jun 30, 21 | 7.19 M
Increased by
+945.49%
|
-11.03 M
Decreased by
-11.09%
|
Decreased by
-153.33%
Increased by
+89.37%
|
| Mar 31, 21 | 3.20 M
Increased by
+193.68%
|
-10.64 M
Decreased by
-92.35%
|
Decreased by
-332.18%
Increased by
+34.50%
|
| Dec 31, 20 | 5.64 M
Increased by
+538.35%
|
-6.34 M
Decreased by
-3.29%
|
Decreased by
-112.39%
Increased by
+83.82%
|
| Rank | ETF | Shares | Market Value | Weight % in ETF |
|---|
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.